Ren Lingyun, Liu Wei, Chen Shanshan, Zeng Haibo
Anesthesiology Department, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Key Laboratory for Molecular Diagnosis of Hubei Province, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Cardiovasc Med. 2024 Apr 17;11:1341918. doi: 10.3389/fcvm.2024.1341918. eCollection 2024.
Our recently published study discovers that exosomal microRNA (miR)-186-5p promotes vascular smooth muscle cell viability and invasion to facilitate atherosclerosis. This research aimed to explore the prognostic implication of serum exosomal miR-186-5p in acute myocardial infarction (AMI) patients receiving percutaneous coronary intervention (PCI).
One hundred and fifty AMI patients receiving PCI and 50 healthy controls (HCs) were screened. Serum exosomal miR-186-5p was detected by reverse transcriptase-quantitative polymerase chain reaction assay in AMI patients at admission and after PCI, as well as in HCs after enrollment. Major adverse cardiac events (MACE) were recorded during follow-up in AMI patients receiving PCI.
Serum exosomal miR-186-5p was raised in AMI patients vs. HCs (< 0.001). Besides, serum exosomal miR-186-5p was positively linked to body mass index (= 0.048), serum creatinine (= 0.021), total cholesterol (= 0.029), and C-reactive protein (= 0.018); while it was reversely linked with estimated glomerular filtration rate (= 0.023) in AMI patients. Interestingly, serum exosomal miR-186-5p was correlated with the diagnosis of ST-segment elevation myocardial infarction (= 0.034). Notably, serum exosomal miR-186-5p was decreased after PCI vs. at admission (< 0.001). The 6-, 12-, 18-, and 24-month accumulating MACE rates were 4.5%, 8.9%, 14.8%, and 14.8% in AMI patients. Furthermore, serum exosomal miR-186-5p ≥3.39 (maximum value in HCs) after PCI (= 0.021) and its decrement percentage <median (35%) decrement (= 0.044) estimated elevated MACE in AMI patients.
Serum exosomal miR-186-5p is reduced after PCI, and its post-PCI high level or minor decrease estimates increased MACE risk in AMI patients.
我们最近发表的研究发现，外泌体微小RNA（miR）-186-5p可促进血管平滑肌细胞的活力和侵袭，从而促进动脉粥样硬化。本研究旨在探讨血清外泌体miR-186-5p对接受经皮冠状动脉介入治疗（PCI）的急性心肌梗死（AMI）患者的预后意义。
筛选150例接受PCI的AMI患者和50例健康对照者（HCs）。采用逆转录定量聚合酶链反应法检测AMI患者入院时、PCI术后以及HCs入组后的血清外泌体miR-186-5p。记录接受PCI的AMI患者随访期间的主要不良心脏事件（MACE）。
与HCs相比，AMI患者血清外泌体miR-186-5p升高（<0.001）。此外，在AMI患者中，血清外泌体miR-186-5p与体重指数（=0.048）、血清肌酐（=0.021）、总胆固醇（=0.029）和C反应蛋白（=0.018）呈正相关；而与估计肾小球滤过率（=0.023）呈负相关。有趣的是，血清外泌体miR-186-5p与ST段抬高型心肌梗死的诊断相关（=0.034）。值得注意的是，与入院时相比，PCI术后血清外泌体miR-186-5p降低（<0.001）。接受PCI的AMI患者6个月、12个月、18个月和24个月的累积MACE发生率分别为4.5%、8.9%、14.8%和14.8%。此外，PCI术后血清外泌体miR-186-5p≥3.39（HCs中的最大值）（=0.021）及其下降百分比<中位数下降（35%）（=0.044）提示AMI患者MACE升高。
PCI术后血清外泌体miR-186-5p降低，其PCI术后高水平或轻微下降提示AMI患者MACE风险增加。
